GLIS3

Across TCGA pan-cancer cohorts, GLIS3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GLIS3 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GLIS3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GLIS3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, PDAC, and CCRCC are the cancer types where GLIS3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	II,III,IV	1.000	0.658	.033	12	view →
PDAC	OS	Median	All	0.262	0.984	.038	6	view →
CCRCC	DFS	Median	II,III,IV	0.404	1.000	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GLIS3–UCEC (OS)

Open the UCEC breakdown →